Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

New date announced for Communiqué Awards 2021!

The awards will now take place on 1 September 2021 at what is hoped will be a live event

- PMLiVE

GCI Health’s UK team announces three senior promotions

Kim Walker, Hannah Morris and Clare Yianni take on new leadership roles

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

- PMLiVE

CureVac expands COVID-19 vaccine trial protocol to include variant specification

Company is aiming to ensure its vaccine efficacy data is 'meaningful' against new virus variants

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts hospitalisation or death by 70%

Phase 3 trial is evaluating the therapy in high-risk non-hospitalised patients with COVID-19

- PMLiVE

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Therapy hit both primary endpoints of overall survival and radiographic progression-free survival

- PMLiVE

A lonely planet

The impact of social isolation and loneliness due to COVID-19 has not yet fully revealed itself

- PMLiVE

EU-UK COVID-19 vaccine row continues as export ban discussion looms

EU officials are set to discuss imposing a vaccine export ban this week

Roche Basel Switzerland

Roche’s Tecentriq yields positive data in early stage NSCLC

PD-L1 inhibitor improved disease-free survival in phase 3 IMpower010 study

- PMLiVE

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

Specific review of thrombotic events found no increased risk of thrombosis associated with vaccine

- PMLiVE

Setting up for success in a post-Brexit, post-pandemic Britain

Creating a new biotech affiliate and seeking marketing authorisation for a new drug in the UK during a pandemic

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links